[HTML][HTML] Optimizing omalizumab dosing in severe asthma—the exploration of therapeutic drug monitoring
JA Kroes, SW Zielhuis, AN Van der Meer… - The Journal of …, 2021 - jaci-inpractice.org
Therapeutic drug monitoring (TDM), measuring drug concentrations to adjust dosing and
optimize treatment outcomes, is commonly applied to personalize costly biological treatment …
optimize treatment outcomes, is commonly applied to personalize costly biological treatment …
Patient-reported outcome measures after 8 weeks of mepolizumab treatment and long-term outcomes in patients with severe asthma: an observational study
JA Kroes, SW Zielhuis, AN Van der Meer… - International journal of …, 2021 - Springer
Background The novel anti-IL-5 drug mepolizumab improves asthma outcomes in the
majority but not all patients with severe eosinophilic asthma. Currently it is difficult to predict …
majority but not all patients with severe eosinophilic asthma. Currently it is difficult to predict …
Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report
JA Kroes, SW Zielhuis, C Bethlehem… - European Journal of …, 2022 - ejhp.bmj.com
A patient with severe asthma on benralizumab therapy was admitted to the intensive care
unit (ICU) for a coronavirus disease 2019 (COVID-19) infection. At the end of the 8 week …
unit (ICU) for a coronavirus disease 2019 (COVID-19) infection. At the end of the 8 week …
[CITATION][C] Lanthanide bearing radioactive particles for cancer therapy and multimodality imaging
SW Zielhuis - 2006 - Utrecht University